Translate
Job title
Consultant medical oncologist
Contact details
PA/secretary tel (Sonalee Vadera):
020 7830 2184 ext 35484
Related services
Location
Biography
Dr Neha Chopra MBBS BSc MRCP PGCert MD(Res) is a medical oncologist specialising in breast cancer at the Royal Free Hospital and Barnet Hospital.
She completed her medical training at University College London in 2001. Her research focused on homologous recombination and PARP inhibitor treatment for triple negative breast cancer and was awarded MD(Res) from the Institute of Cancer Research and the Royal Marsden Hospital.
Dr Chopra has a keen interest in undergraduate teaching and is currently the undergraduate lead for oncology at the Royal Free Hospital.
GMC number
6164193
• Cancer history and systemic anti-cancer therapy independently predict COVID-19 mortality: A UK tertiary hospital experience Sng C, Wong S, Wu A, Chopra N, Galazi M, Benafif S, Soosaipillai G, Roylance R, Lee A, Shaw H. Frontiers in Oncology. 2020 Nov 20
• Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic Younger E, Smrke A, Lidington E, Farag S, Ingley K, Chopra N, Maleddu A, Augustin Y, Merry E, Wilson R, Benson C, Miah A, Zaidi S, McTiernan A, Strauss SJ, Dileo P, Gennatas S, Husson O, Jones RL. Cancers. 2020; 12(8):2288.
• Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers Yap, T. A., Kristeleit, R., Michalarea, V., Pettitt, S. J., Lim, J., Carreira, S., Roda, D., Miller, R., Riisnaes, R., Miranda, S., Figueiredo, I., Nava Rodrigues, D., Ward, S., Matthews, R., Parmar, M., Turner, A., Tunariu, N., Chopra, N., Gevensleben, H., Turner, N. C., … de Bono, J. S. (2020). Cancer discovery 2020 Oct; 10(10):1528-1543
• Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC. Nat Commun. 2020 May 29;11(1):2662.
• Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer Garcia-Murillas I*, Chopra N*, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC. JAMA Oncol. 2019 Aug 1;5(10):1473-8.
• Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience Battisti NML, True V, Chaabouni N, Chopra N, Lee K, Shepherd S, Shapira-Rotenberg T, Joshi R, McGrath S, Okines A, Parton M, Turner N, Mohammed K, Allen M, Johnston S, Ring A. Breast Cancer Res Treat. 2020 Jan;179(1):101-111. doi: 10.1007/s10549-019-05444-0. Epub 2019 Sep 18.
• Cancer in low- and middle-income countries: time for action Hack B, Piddock K, Stanway S, Balachandran K, Board R, Chopra N, Okonji D, Sirohi B, Sullivan R, Wakeham K. J S Soc Med. 2019; Jun;112(6):213-217